The World Health Organization (WHO) has announced the approval of the first diagnostic test for mpox (formerly known as monkeypox) under its Emergency Use Listing (EUL) procedure. This significant milestone aims to enhance global diagnostic capacity amid rising mpox outbreaks.
The approved test, the Alinity m MPXV assay, developed by Abbott Molecular Inc., is a real-time PCR test designed to detect the mpox virus from human skin lesion swabs. This test will be pivotal in expanding diagnostic capabilities in countries facing mpox outbreaks, where the need for quick and accurate testing has become critical.
The Alinity m MPXV assay allows for the rapid detection of mpox virus DNA, enabling timely diagnosis and treatment.
The EUL procedure is designed to expedite the availability of essential health products during public health emergencies. By assessing the quality, safety, and performance of diagnostic tests, the WHO aims to guide procurement agencies and member states in making informed decisions for emergency procurement.